CD274 and non-small cell lung carcinoma: Moreover, a retrospective analysis of a phase III study (NCT03607539) involving patients with non-small cell lung cancer (NSCLC) showed that PD-L1 TPS ≥ 50% more reliably predicted the response to anti-PD1 combination therapy in patients with baseline large tumors compared to those with small ones.